OZ Biosciences expands its transfection solutions portfolio with the launch of Magnetofectamine Kit.
OZ Biosciences, a French group specialising in the development of transfection technologies, has announced the launch of Magnetofectamine, a new product in its line of transfection reagents.
Ideal to transfect primary and hard-to-transfect cells, Magnetofectamine is a combination of Lipofectamine 2000, a transfection reagent from Life Technologies Corporation, with Magnetofection-based reagent CombiMag, from OZ Biosciences.
The companies claim that the alliance of Lipofectamine 2000 and CombiMag reagent leads to increased transfection efficiency, minimised toxicity and enhanced gene expression.
Magnetofection is a method to transfect cells in vitro and in vivo.
The magnetic assisted transfection is based on the use of magnetic nanoparticles associated to the nucleic acid.
In this way, the magnetic force allows a rapid concentration of genetic material onto cells and promotes cellular uptake.
Lipofectamine 2000 is a transfection reagent for a simple and effective nucleic acid delivery (DNA and siRNA).
In the presence of CombiMag reagent, Lipofectamine 2000 delivers DNA at higher efficiencies, from +30 to 500 per cent.
With Magnetofectamine, the company claims that up to 75 per cent transfection efficiencies can be achieved into many primary cells, such as endothelial, chondrocytes, epithelial and human mesenchymal stem cells.
